Neuropace, Inc. Announces Addition of Lisa Andrade to the Board
October 19, 2021 at 04:03 pm EDT
Share
NeuroPace, Inc. announced the addition of Lisa Andrade to its Board of Directors. Simultaneously, the company also announced the resignation of current board member, Evan Norton. Both changes are effective November 1, 2021. Lisa Andrade joins NeuroPace with over 25 years of experience in both large and early-stage medtech, software and technology companies. Currently, Ms. Andrade is CEO of M33, an executive coaching and leadership development firm, which she founded in 2018. Prior to founding M33, she served as Chief Marketing Officer at St. Jude Medical, a global medical device company, which was acquired by Abbott in 2017. Ms. Andrade has held numerous executive leadership positions in engineering, research, product development, strategy, product management, marketing, healthcare economics and sales. She has been instrumental in the development and commercialization of numerous innovative medical devices and software products in the healthcare market and has been awarded multiple patents.
NeuroPace, Inc. is a medical device company. The Company is focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is a brain-responsive platform that delivers personalized, real-time treatment at the seizure source. The Company has developed its RNS System to address the individualized nature of drug-resistant epilepsy and deliver a safe therapy for focal onset seizures anywhere in the brain. The RNS System is a device that records brain activity data and allows clinicians to monitor patients not only in person, but also remotely. RNS System monitors and analyzes the brainâs electrical activity, recognizes patient-specific abnormal patterns, and delivers treatment at the seizure source. The Companyâs RNS System is also engaged in treating other brain disorders, including depression, impulse control disorders, memory disorders, and post-traumatic stress disorder.